Novo Nordisk A/S
- Country
- 🇩🇰Denmark
- Ownership
- Public
- Established
- 1923-01-01
- Employees
- 63.3K
- Market Cap
- $602.2B
- Website
- http://www.novonordisk.com
Research Study Looking at How Well Semaglutide Works in People Living With Obesity and Prediabetes
- First Posted Date
- 2021-09-10
- Last Posted Date
- 2024-10-28
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 207
- Registration Number
- NCT05040971
- Locations
- 🇨🇦
University of Calgary, Calgary, Alberta, Canada
🇨🇦C-endo Diab Endo Clin Calgery, Calgary, Alberta, Canada
🇨🇦LMC Clin Res Inc. Thornhill, Concord, Ontario, Canada
A Research Study Comparing RYBELSUS® to Other Blood Sugar Lowering Tablets in People Living in America With Type 2 Diabetes (REALYSE)
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Drug: oral glucose-lowering medications (commercially available)
- First Posted Date
- 2021-09-05
- Last Posted Date
- 2025-04-29
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 1262
- Registration Number
- NCT05035082
- Locations
- 🇺🇸
WakeMed Garner Hlthplx, Garner, North Carolina, United States
🇺🇸FDRC, Costa Mesa, California, United States
🇺🇸Scripps Whittier Diabetes Inst, La Jolla, California, United States
Research Study to Investigate How Well Semaglutide Tablets Taken Once Daily Work in People Who Are Overweight or Living With Obesity (OASIS 1)
- Conditions
- ObesityOverweight
- Interventions
- Drug: Placebo (semaglutide)
- First Posted Date
- 2021-09-05
- Last Posted Date
- 2024-07-08
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 667
- Registration Number
- NCT05035095
- Locations
- 🇺🇸
East West Med Res Inst, Honolulu, Hawaii, United States
🇫🇷Groupe Sos Sante-Hopital Le Creusot-Hotel Dieu-2, Le Creusot, France
🇩🇪InnoDiab Forschung GmbH, Essen, Germany
ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation
- Conditions
- Cardiovascular RiskChronic Kidney DiseaseInflammation
- Interventions
- Drug: Ziltivekimab BDrug: Placebo (Ziltivekimab B)Drug: Ziltivekimab CDrug: Placebo (Ziltivekimab C)
- First Posted Date
- 2021-08-26
- Last Posted Date
- 2025-05-07
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 6200
- Registration Number
- NCT05021835
- Locations
- 🇹🇷
Istanbul University Cardiology Institute, Istanbul, Turkey
🇦🇷Instituto Médico DAMIC, Córdoba, Argentina
🇦🇷Instituto Médico CER, Quilmes - Buenos Aires, Argentina
A Research Study Looking Into Blood Levels of the Medicine NNC0480-0389 in Participants With Reduced Kidney Function Compared to Participants With Normal Kidney Function
- First Posted Date
- 2021-08-23
- Last Posted Date
- 2023-11-13
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 42
- Registration Number
- NCT05015894
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Berlin, Germany
Research Study on Whether a Combination of 2 Medicines (NNC0194 0499 and Semaglutide) Works in People With Non-alcoholic Steatohepatitis (NASH)
- Conditions
- Non-alcoholic Steatohepatitis
- Interventions
- Drug: NNC0194 0499 50 mg/mLDrug: Placebo (NNC0194-0499)Drug: NNC0174 0833 10 mg/mLDrug: NNC0174 0833 placebo
- First Posted Date
- 2021-08-23
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 698
- Registration Number
- NCT05016882
- Locations
- 🇺🇸
Gastroenterology Assoc_ CGA, Macon, Georgia, United States
🇺🇸Gastroint Spec of Georgia, Marietta, Georgia, United States
🇺🇸Texas Diabetes &Endocrinology, Round Rock, Texas, United States
Awareness, Care & Treatment In Obesity Management - An International Observation Among Teens (ACTION Teens)
- Conditions
- Obesity
- Interventions
- Other: No treatment given
- First Posted Date
- 2021-08-19
- Last Posted Date
- 2022-02-02
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 12987
- Registration Number
- NCT05013359
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Gatwick, United Kingdom
A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Insulin Glargine Taken Daily With Insulin Aspart (COMBINE 3)
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2021-08-19
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 679
- Registration Number
- NCT05013229
- Locations
- 🇺🇸
Endeavor Health, Skokie, Illinois, United States
🇺🇸Andres Garcia-Zuniga, MD, P.A, Laredo, Texas, United States
🇫🇷Centre de Recherche Clinique Portes Du Sud, Venissieux, France
A Research Study Looking at How the Medicine NNC0385-0434 Works in the Body of Healthy Japanese Men
- Conditions
- Atherosclerotic Cardiovascular DiseaseHealthy Volunteers
- Interventions
- Drug: Placebo
- First Posted Date
- 2021-08-12
- Last Posted Date
- 2024-01-17
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 36
- Registration Number
- NCT05003440
- Locations
- 🇯🇵
Hakata Clinic, Fukuoka, Japan
Research Study Investigating How Well Semaglutide Works in People From Thailand and South Korea Living With Obesity
- Conditions
- Obesity
- Interventions
- Drug: Placebo (semaglutide 2.4 mg)
- First Posted Date
- 2021-08-10
- Last Posted Date
- 2025-04-03
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 150
- Registration Number
- NCT04998136
- Locations
- 🇰🇷
Ajou University Hospital, Suwon, Korea, Republic of
🇹🇭Obstetrics&Gynecology King Chulalongkorn Memorial Hospital, Bangkok, Thailand
🇹🇭Siriraj Hospital_Bangkok_1, Bangkok, Thailand